Alemtuzumab induction therapy in kidney transplantation - Authors' reply.
Clinical Trial Service Unit, and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK; Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK. Electronic address: richard.haynes@ctsu.ox.ac.uk.
Richard
R
Haynes
Clinical Trial Service Unit, and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Colin
C
Baigent
Clinical Trial Service Unit, and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Martin J
MJ
Landray
Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK.
Paul
P
Harden
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Peter
P
Friend
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000077552:Basiliximab; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000074323:Alemtuzumab; D000077552:Basiliximab